Shares of Dr. Agarwal’s Health Care surged 5.5% following strong first-quarter FY27 results. The company reported a 44.6% rise in profit, driven by a 26% increase in revenue. Alongside the financial growth, the company announced international expansion plans in Nigeria, prompting analysts to revise their price targets.
Shares of Dr. Agarwal’s Health Care climbed 5.5% on Wednesday, closing at ₹515.80 on the National Stock Exchange. The upward move followed the company’s announcement of robust financial performance for the first quarter of the 2027 fiscal year. Investors reacted positively to both the profit growth and the company's strategic expansion into international markets.
The company reported a 44.6% year-on-year increase in profit after tax, reaching ₹55 crore for the quarter ending in June 2026. Revenue from operations also saw a significant rise of 26%, climbing to ₹614 crore. This performance was supported by strong operational efficiency, with Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increasing by 25.2% to ₹177 crore. The company maintained steady operating margins of 28.5% even while continuing its expansion efforts.
Dr. Agarwal’s Health Care is currently in an aggressive growth phase. During the first quarter, the company added 18 new facilities, bringing its total network to 304 eye care centers. Furthermore, the board has approved the incorporation of a wholly owned subsidiary in Nigeria, marking a fresh attempt to tap into international markets. This strategy suggests the company is looking to replicate its hub-and-spoke model beyond India to find new sources of revenue.
Following the financial update, global brokerages have updated their outlooks. Analysts at Morgan Stanley maintained an 'overweight' rating and increased their price target to ₹576, citing strong execution and revenue growth. Similarly, Jefferies maintained an 'accumulate' rating and raised its target to ₹600. These analysts pointed to the company’s ability to drive same-store sales growth and the benefit of offering higher-value eye care services.
While the expansion signals growth, investors should also consider the potential risks. Rapid expansion often brings execution challenges, particularly when entering new geographic territories like Nigeria, where market dynamics may differ. Additionally, the company faces the risk of sequential margin pressure as it absorbs the initial costs of launching and scaling new centers. Maintaining profitability while managing debt and operating expenses across a larger footprint will be a key challenge.
The next important monitorables for shareholders will be the pace of new center commissioning and the financial contribution from the new international subsidiary. Investors may also track whether the company can sustain its same-store sales growth, which has been a primary driver of its performance in recent quarters.